Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q3 2021 results, highlighting operational progress in its pivotal clinical programs for KSI-301 targeting retinal diseases. The company anticipates topline data readouts starting in early 2022, with significant studies such as DAZZLE and BEACON scheduled. As of September 30, 2021, Kodiak holds $799.2 million in cash, but reported a net loss of $67.5 million, up from $36.1 million in Q3 2020. Total R&D expenses reached $56 million, reflecting increased clinical trial costs.
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in two virtual investor conferences. The first is the Jefferies London Healthcare Conference on November 18, where a pre-recorded fireside chat will be available at 12:00 a.m. PT. The second event is the Evercore ISI 4th Annual HealthCONx Conference on December 1, starting at 8:45 a.m. PT. Live webcasts will be accessible in the "Events and Presentations" section of Kodiak's website, with replays available following the events.
Kodiak Sciences Inc. (Nasdaq: KOD) has introduced a Long-Term Performance Incentive Plan (LTPIP) for its named executive officers and eligible employees, pending stockholder approval at an upcoming meeting in October. Participants can opt to forego up to 75% of their annual equity awards for seven years in exchange for performance-based stock options that can yield three times the value. Key milestones include stock price increases to $200 and ultimately $800 per share. Additional operational milestones involve FDA approvals and achieving over $2.5 billion in sales.
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 8:45 a.m. PT. The presentation will focus on the company's innovative therapeutics for retinal diseases. A live webcast will be accessible via the company's website and available for replay post-event. Kodiak is dedicated to advancing treatments for conditions like age-related macular degeneration and diabetic eye diseases using its proprietary ABC Platform™.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its second quarter 2021 results, highlighting significant progress in several clinical trials, including the DAZZLE and BEACON studies. The company ended Q2 with $880.9 million in cash, but reported a net loss of $55.9 million, increasing from $26.0 million a year earlier. R&D expenses rose sharply to $45.4 million due to escalating clinical trial costs. Additionally, Kodiak's IND approvals in China aim to enhance global trial participation for its KSI-301 product, with topline data expected in early 2022.
Kodiak Sciences Inc. (Nasdaq: KOD) has announced its participation in two upcoming virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 PM PT, and the second is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:40 PM PT. Both presentations will be available via live webcast on the company's website, with replays offered afterward. Kodiak focuses on developing therapeutics for retinal diseases, leveraging its ABC Platform™.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q1 2021 financial results, highlighting a net loss of $50.4 million, or $0.98 per share, compared to a net loss of $24.4 million in Q1 2020. Cash and equivalents stood at $929 million. The company is making significant progress in its pivotal studies for KSI-301, with the DAZZLE study fully enrolled and the launch of the DAYLIGHT study planned for summer 2021, aiming to broaden product labeling. R&D expenses increased to $40.3 million, driven by higher clinical trial costs. G&A expenses rose to $10.2 million due to payroll increases.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on retinal diseases, will present at two upcoming virtual investor conferences. The first is the Truist Securities 2021 Life Sciences Summit on May 4 at 8:20 a.m. PT, and the second is the UBS Global Healthcare Virtual Conference on May 25 at 12:00 p.m. PT. A live webcast will be available on Kodiak's website and can be replayed for a limited time. Kodiak is known for its ABC Platform™ and lead product candidate KSI-301, targeting major retinal vascular diseases.
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in two virtual investor conferences. The Barclays Global Healthcare Conference is scheduled for March 10 at 8:30 a.m. PT, and the J.P. Morgan Napa Valley Forum will occur on March 31 at 8:00 a.m. PT. Both presentations will be available via live webcast on Kodiak's website, with replays accessible for a limited time after the events. Kodiak focuses on developing therapies for retinal diseases, leveraging its innovative ABC Platform™ to advance its product candidates, including KSI-301.
Kodiak Sciences Inc. (Nasdaq: KOD) reported Q4 2020 financial results, revealing a net loss of $46.6 million, or $0.97 per share, up from a $15.6 million loss in Q4 2019. The company's cash position improved to $969 million, boosted by a $612 million equity offering. Phase 1b data for KSI-301 showed significant treatment durability, with two-thirds of patients achieving a 6-month treatment-free interval after three doses. Kodiak is advancing its pivotal clinical studies, including DME and RVO, with key milestones expected in 2022.